India launches national policy on R&D and innovation in pharma-medtech sector

Union Minister of Chemicals and Fertilizers and Minister of Health & Family Welfare, Dr Mansukh Mandaviya, yesterday unveiled the National Policy on Research and Development and Innovation in the Pharma-MedTech Sector in India. The event also marked the launch of the Scheme for the promotion of Research and Innovation in the Pharma MedTech Sector (PRIP). Other dignitaries present at the event included Dr V. K. Paul from NITI Aayog, Ms. S Aparna, Secretary (Pharma), and Dr Rajiv Bahl, Director General, ICMR.

Highlighting the profound impact of the policy, Dr Mandaviya expressed his confidence in it transforming India into a significant global player in the pharmaceutical sector. The scheme aims to achieve high quality, accessibility, and affordability goals while bolstering India’s presence in the international pharmaceutical industry. “The policy will help create an ecosystem including academia and private sectors, fuelling new talent and start-ups,” remarked Dr Mandaviya.

Amidst echoes of ‘Jai Jawan, Jai Kisan, Jai Vigyan, and Jai Anusandhan’, the minister emphasized India’s commitment to innovation and growth in brain power and manpower. He outlined the establishment of three bulk drug parks and four medical device parks across various states to reinforce this sector.

Dr Mandaviya further stressed the importance of strengthening India’s research and development infrastructure, a move pivotal for the nation’s self-reliance in pharmaceuticals and medical devices. The focus is on creating policies and new products aligned with both national and global needs, in concert with industries and academia.

Dr V K Paul reiterated India’s leadership and foresight in the global arena. He underscored the importance of collaboration among academia, public, and private institutions for overcoming future challenges and ensuring national biosecurity.

Expected benefits of the scheme include the enhancement of research infrastructure, promotion of industry-academia linkages, and focus on priority areas for bolstering India’s global standing in pharmaceutical innovation. It will also aid in the launch of commercially viable products, driving revenue growth and employment opportunities in the Indian pharmaceutical sector. Additionally, the scheme is anticipated to contribute to the development of affordable and accessible healthcare solutions, thereby easing the national healthcare burden.

This launch marks a significant step towards the enhancement of India’s pharmaceutical and med-tech sectors, reinforcing the nation’s commitment to self-reliance, innovation, and global leadership in healthcare.

Follow and connect with us on

Related News